FDA: No Long-Term Clopidogrel Mortality, Cancer Risks FDA: No Long-Term Clopidogrel Mortality, Cancer Risks

In today's MedWatch, the agency reports results from its meta-analyses, which included a review of DAPT and other large clinical trials that examined adverse events from clopidogrel use. News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news